MaterniT21 Plus Test Adoption Drives Sequenom Q2 Revenues up 38 Percent
July 26, 2012
MaterniT21 Plus Test Adoption Drives Sequenom Q2 Revenues up 38 Percent
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Sequenom Appeals Federal Court Denial of Preliminary Injunction Against Ariosa
July 17, 2012 / GenomeWeb Daily News - ACMG Cautious of Non-invasive Prenatal Diagnostic Testing in Policy Statement
April 8, 2013 / GenomeWeb Daily News - Cost Effectiveness Study Shows Sequencing-Based T21 Test Leads to Better Clinical Outcomes
May 2, 2012 / Clinical Sequencing News - Sequenom Boosts Prenatal IP Portfolio with Helicos Patents; Raises MaterniT21 Sales Projections
April 18, 2012 / Clinical Sequencing News - As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012 / Clinical Sequencing News